Stockscreener 앱 받기
14.66
1.95%
0.28
Trevi Therapeutics Inc 주식(TRVI)의 최신 뉴스
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 - Investing.com
Trevi Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Trevi Therapeutics Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan
Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan
Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
MSN Money - MSN
Pictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
Trevi Therapeutics, Inc. Announces Oral Nalbuphine Extended-Release Clinical Trial Results And Presentations - marketscreener.com
Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Trevi Therapeutics (TRVI.US) is scheduled to release its earnings report after the market closes on May 5. - Moomoo
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN
Trevi Therapeutics Closes $173 Million Public Offering - Global Legal Chronicle
Clinical-stage biotech Trevi sets May 5 webcast for Q1 results - Stock Titan
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - marketscreener.com
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - Quantisnow
Trevi Therapeutics launches $150M public stock offering - MSN
Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics to Participate in Upcoming May Events - The Manila Times
New Haven-based Trevi Therapeutics raises $173M in public offering - Hartford Business Journal
Trevi lines up a May 7 investor day and May 12 conference webcast - Stock Titan
Trevi Therapeutics (TRVI) Stock: Is It Holding Support | Q4 2025: Earnings Beat EstimatesEquity Raise - Cổng thông tin điện tử Tỉnh Sơn La
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative? - Yahoo Finance
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Trevi Therapeutics (NASDAQ: TRVI) asks holders to OK share, equity plan boosts - Stock Titan
[ARS] Trevi Therapeutics, Inc. SEC Filing - Stock Titan
Leerink raises Trevi Therapeutics stock price target on ILD outlook By Investing.com - Investing.com Canada
Trevi Therapeutics Closes $173 Million Share Offering - marketscreener.com
Trevi Therapeutics announces closing of $173 million underwritten offering - marketscreener.com
Trevi Therapeutics Announces Closing Of $173 Million Underwritten Offering - TradingView
Press Release: Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Moomoo
Can Trevi Therapeutics Address The Big Unmet Need In Chronic Cough? - RTTNews
Trevi Therapeutics (TRVI) Stock: Slowing Down? (Breakout Watch) 2026-04-18Trending Picks - Cổng thông tin điện tử tỉnh Tây Ninh
What's Going On With Trevi Therapeutics Stock? - Sahm
Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
TRVI Maintains Buy Rating by D. Boral Capital -- Price Target Un - GuruFocus
0.14%
0.48%
자본화:
|
볼륨(24시간):